Cowen & Co. Remains a Buy on Foamix Pharma (FOMX)

Cowen & Co. analyst Ken Cacciatore maintained a Buy rating on Foamix Pharma (NASDAQ: FOMX) on September 12 and set a price target of $30. The company’s shares closed yesterday at $6.18.

According to, Cacciatore is a 3-star analyst with an average return of 5.0% and a 49.1% success rate. Cacciatore covers the Healthcare sector, focusing on stocks such as Liquidia Technologies Inc, Jazz Pharmaceuticals, and Horizon Pharma Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Foamix Pharma with a $22 average price target, which is a 256.0% upside from current levels. In a report issued on September 12, H.C. Wainwright also reiterated a Buy rating on the stock with a $14 price target.


See today’s analyst top recommended stocks >>

The company has a one-year high of $7.60 and a one-year low of $4.40. Currently, Foamix Pharma has an average volume of 514K.

Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Foamix Pharmaceuticals Ltd. is a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel.

From Our Partners